Skip to main content

Table 2 Clinical and demographic features of the metabotypes identified thought KODAMA analysis

From: Inflammatory metabolic profile of South African patients with prostate cancer

Feature Metabotype I Metabotype II Metabotype III Metabotype IV p value
NCCN classification, n (%)      1.14 × 10−1
 Very low 1 (33.3) 0 (0.0) 1 (7.1) 0 (0.0)  
 Low 0 (0.0) 1 (10.0) 1 (7.1) 1 (14.3)  
 Intermediate 2 (66.7) 4 (40.0) 3 (21.4) 0 (0.0)  
 High 0 (0.0) 3 (30.0) 4 (28.5) 0 (0.0)  
 Very high 0 (0.0) 2 (20.0) 5 (35.7) 5 (71.4)  
 Metastatic 0 (0.0) 0 (0.0) 0 (0.0) 1 (14.3)  
Gleason score, n (%)      9.00 × 10−2
 3 + 3 1 (33.3) 1 (10.0) 5 (35.7) 1 (14.3)  
 3 + 4 1 (33.3) 4 (40.0) 6 (42.9) 0 (0.0)  
 4 + 3 1 (33.3) 1 (10.0) 0 (0.0) 0 (0.0)  
 3 + 5 0 (0.0) 0 (0.0) 0 (0.0) 1 (14.3)  
 4 + 5 0 (0.0) 4 (40.0) 3 (21.4) 0 (0.0)  
 5 + 4 0 (0.0) 0 (0.0) 0 (0.0) 2 (28.6)  
 5 + 5 0 (0.0) 0 (0.0) 0 (0.0) 3 (42.9)  
Age, median [95% CI] 71 [64 74] 68 [56 90] 65 [51 85] 74 [59 78] 9.49 × 10−1
Ancestry, n(%)      4.11 × 10−1
 Black 1 (33.3) 1 (10.0) 2 (14.3) 3 (42.9)  
 Mixed ancestry 1 (33.3) 7 (70.0) 11 (78.6) 2 (28.6)  
 White 1 (33.3) 2 (20.0) 1 (7.1) 2 (28.6)  
PSA, median [95% CI] 9 [3 9] 18 [5 233] 25 [5 126] 738 [26 5000] 5.89 × 10−3
Diabetes, n (%)      8.85 × 10−2
 No 1 (33.3) 7 (70.0) 13 (92.9) 7 (100.0)  
 Yes 2 (66.7) 3 (30.0) 1 (7.1) 0 (0.0)  
Hypertension, n (%)      1.18 × 10−1
 No 0 (0.0) 8 (80.0) 9 (64.3) 6 (85.7)  
 Yes 3 (100.0) 2 (20.0) 5 (35.7) 1 (14.3)  
Smoker, n (%)      4.37 × 10−1
 No 2 (66.7) 8 (80.0) 9 (64.3) 7 (100.0)  
 Yes 1 (33.3) 2 (20.0) 5 (35.7) 0 (0.0)